Organisation profile
Fields of science
- 302016 Gastroenterology
- 302025 Hepatology
- 302030 Internal medicine
Profiles
-
CHARGE: A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohn’s Disease
Moschen, A. (PI), Kainberger, M. (Administration), Doringer, D. (Administration), Prommer, R. (Researcher), Rathenböck, M. (Researcher) & Klenske, E. (Researcher)
01.04.2026 → 23.04.2030
Project: Clinical studies › Clinical Study (Industry project)
-
RESURGE – Randomized Controlled Comparative Phase II Trial on Surgery for Glioblastoma Recurrence
Heil, K. (Researcher), Rauch, P. (Researcher), Böhm, V. (Researcher), Höllmüller, I. (Researcher), Pichler, J. (Researcher), Leibetseder, A. (Researcher) & Schucht, P. (Researcher)
01.11.2025 → 31.12.2027
Project: Funded research › Other sponsors
-
VICTRIVA: A Randomized, Double-blind, Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With lntravenous Vedolizumab and Oral Upadacitinib Compared With lntravenous Vedolizumab and Oral Placebo for lnduction Followed by lntravenous Vedolizumab Monotherapy for Maintenance in the Treatment of Adults With Moderately to Severely Active Crohn's Disease
Moschen, A. (PI), Prommer, R. (Co-PI), Klenske, E. (Researcher), Pimingstorfer, P. (Researcher), Rathenböck, M. D. (Researcher), Kainberger, M. (Administration), Zaunmair, P. (Administration) & Doringer, D. (Administration)
28.03.2025 → 27.03.2030
Project: Clinical studies › Clinical Study (Industry project)
-
Case Report: Diagnostic challenges in VEXAS syndrome with novel ultrastructural lung findings: IgG4-RD and vasculitis as relevant differential diagnoses
Etzel, P., Lang, D., Öberseder, G. & Lamprecht, B., 21 Jan 2026, In: Frontiers in Immunology. 16, 7 p., 1742328.Research output: Contribution to journal › Article › peer-review
Open Access -
Design of CellProfiler-based pipelines enabling the attribution of molecular stress markers to specific tissue and subcellular compartments of the colonic mucosa
Hödlmayr, H., Watschinger, C., Wallner, G. K., Knipp, S., Rohwedder, A., Prommer, R., Langer, R. & Moschen, A. R., 2026, In: Cellular and Molecular Gastroenterology and Hepatology. 20, 6, 44 p., 101680.Research output: Contribution to journal › Article › peer-review
Open Access -
Reply to: When ground truth is not static: rethinking AI performance in occlusive MI detection from post-MI ECGs
Silwanis, C., Groche, M., Steinwender, C. & Lambert, T., May 2026, In: Resuscitation. 222, 110928.Research output: Contribution to journal › Article › peer-review
Open Access
Activities
-
Ontunisertib – ALK5-Blockade bei fistulierendem Morbus Crohn
Moschen, A. (Speaker)
18 Feb 2026Activity: Talk or presentation › Invited talk › science-to-science
-
GUS Advisory Board - Johnson & Johnson
Moschen, A. (Participant)
04 Dec 2025Activity: Participating in or organising an event › Participating in a conference, workshop, ...
-
Rien ne va plus - Management von therapierefraktären Stenosen
Pimingstorfer, P. (Speaker)
29 Nov 2025Activity: Talk or presentation › Invited talk › science-to-science